BRIEF published on 06/30/2025 at 14:05, 7 months 18 days ago Promising Phase 1b Results for invIOs's APN401 Cell Therapy in Advanced Tumors Cell Therapy Phase 1b Trial InvIOs GmbH APN401 Advanced Tumors
BRIEF published on 06/30/2025 at 14:05, 7 months 18 days ago Résultats prometteurs de phase 1b pour la thérapie cellulaire APN401 d'invIOs dans les tumeurs avancées Thérapie Cellulaire InvIOs GmbH APN401 Essai De Phase 1b Tumeurs Avancées
PRESS RELEASE published on 06/30/2025 at 14:00, 7 months 18 days ago invIOs reports promising Phase 1b results for cell therapy APN401 in advanced solid tumors invIOs reports successful Phase 1b trial results for APN401 cell therapy in advanced solid tumors, showing safety and efficacy in late-stage cancer patients Solid Tumors Cell Therapy Phase 1b Trial InvIOs APN401
BRIEF published on 12/16/2024 at 15:05, 1 year 2 months ago InvIOs to Highlight Oncology Pipeline Progress at JP Morgan Week 2025 Oncology Cancer Research Cell Therapy Glioblastoma InvIOs GmbH
BRIEF published on 12/16/2024 at 15:05, 1 year 2 months ago InvIOs mettra en avant les progrès du pipeline oncologique lors de la JP Morgan Week 2025 Thérapie Cellulaire Oncologie Glioblastome Recherche Sur Le Cancer InvIOs GmbH
PRESS RELEASE published on 12/16/2024 at 15:00, 1 year 2 months ago invIOs to present progress across oncology pipeline during JP Morgan Week 2025 invIOs GmbH to present progress in oncology pipeline at JP Morgan Week 2025, including updates on glioblastoma treatments INV501 and INV441 in collaboration with DFCI Oncology Pipeline InvIOs GmbH JP Morgan Week 2025 Glioblastoma Treatments DFCI Collaboration
BRIEF published on 10/15/2024 at 10:35, 1 year 4 months ago InvIOs Secures €8.2 Million Series A Funding for Immuno-oncology Innovations Biotechnology Fundraising Clinical Trials Immuno-oncology InvIOs GmbH
BRIEF published on 10/15/2024 at 10:35, 1 year 4 months ago InvIOS obtient un financement de série A de 8,2 millions d'euros pour des innovations en immuno-oncologie Biotechnologie Essais Cliniques Immuno-oncologie Collecte De Fonds InvIOs GmbH
PRESS RELEASE published on 10/15/2024 at 10:30, 1 year 4 months ago invIOs raises €8.2 million in a Series A to finance pipeline progress in immuno-oncology invIOs GmbH raises €8.2 million in Series A funding to advance immuno-oncology pipeline progress through 2025, collaborating with Dana-Farber Cancer Institute Series A Funding Immuno-oncology Pipeline Progress InvIOs Dana-Farber Cancer Institute
BRIEF published on 07/17/2024 at 10:05, 1 year 7 months ago InvIOs Selects INV501 Lead Candidate for IND-Enabling Studies in Glioblastoma and Melanoma Cancer Therapy Melanoma Preclinical Studies INV501 Glioblastoma
Published on 02/18/2026 at 19:10, 1 hour 38 minutes ago Secure Blockchain Announces Definitive Agreement to Acquire Agentic Solutions Limited, Private Placement and Debt Settlement
Published on 02/18/2026 at 15:15, 5 hours 33 minutes ago Host of "The Schaftlein Report" on Patriot.TV Delivers Urgent Warning to Trump: 2026 Midterm Course Correction Needed Now
Published on 02/18/2026 at 15:00, 5 hours 48 minutes ago Jaguar Health Announces a Special One-time Stock Dividend
Published on 02/18/2026 at 14:25, 6 hours 23 minutes ago Mako Mining Announces Amended and Restated Definitive Agreements for Restructure of Mt. Hamilton Acquisition Consideration and Filing of Supplement to Management Information Circular
Published on 02/18/2026 at 14:00, 6 hours 48 minutes ago Revolve Achieves Key Interconnection Milestone On 130 MW "El 24 Wind Project" In Mexico
Published on 02/18/2026 at 19:11, 1 hour 37 minutes ago flatexDEGIRO adopts new capital allocation policy – increase in annual dividend by a factor of seven planned; 2025 guidance slightly exceeded
Published on 02/18/2026 at 18:54, 1 hour 54 minutes ago EQS-Adhoc: flatexDEGIRO SE: Management and Supervisory Board adopt new capital allocation policy; dividend increase to 20% of Net Income targeted; FY 2025 guidance slightly exceeded
Published on 02/18/2026 at 18:21, 2 hours 27 minutes ago Fuller, Smith & Turner PLC: Transaction in own shares
Published on 02/18/2026 at 18:00, 2 hours 48 minutes ago E-PANGO : Décision du Tribunal administratif de Paris en date du 16 février 2026
Published on 02/18/2026 at 18:00, 2 hours 48 minutes ago Publication du nombre d’actions composant le capital et du nombre total de droits de vote au 31 janvier 2026
Published on 02/18/2026 at 18:00, 2 hours 48 minutes ago Outstanding Shares and Voting Rights Statement at 31 January 2026
Published on 02/18/2026 at 17:40, 3 hours 8 minutes ago GROUPE ES - Communiqué sur les résultats 2025
Published on 02/18/2026 at 13:45, 7 hours 3 minutes ago NRJ GROUP - Non renouvellement Licence FM Nationale NRJ Suède
